The global immunology market size is valued at USD 119.63 billion in 2025 and is forecasted to attain around USD 286.38 billion by 2034, accelerating at a CAGR of 10.20% from 2025 to 2034. The North America immunology market size surpassed USD 57.45 billion in 2024 and is expanding at a CAGR of 10.22% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immunology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immunology Market, by Drug Class
8.1.1 Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast
8.1.2. Fusion Proteins
8.1.2.1. Market Revenue and Forecast
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Immunology Market, by Disease Indication
9.1.1. Rheumatoid Arthritis
9.1.1.1. Market Revenue and Forecast
9.1.2. Psoriatic Arthritis
9.1.2.1. Market Revenue and Forecast
9.1.3. Plaque Psoriasis
9.1.3.1. Market Revenue and Forecast
9.1.4. Ankylosing Spondylitis
9.1.4.1. Market Revenue and Forecast
9.1.5. Inflammatory Bowel Disease
9.1.5.1. Market Revenue and Forecast
9.1.6. Prophylaxis Of Organ Rejection
9.1.6.1. Market Revenue and Forecast
10.1. Immunology Market, by Distribution Channel
10.1.1. Hospital Pharmacie
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class
11.1.2. Market Revenue and Forecast, by Disease Indication
11.1.3. Market Revenue and Forecast, by Distribution Channel
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class
11.1.4.2. Market Revenue and Forecast, by Disease Indication
11.1.4.3. Market Revenue and Forecast, by Distribution Channel
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class
11.1.5.2. Market Revenue and Forecast, by Disease Indication
11.1.5.3. Market Revenue and Forecast, by Distribution Channel
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class
11.2.2. Market Revenue and Forecast, by Disease Indication
11.2.3. Market Revenue and Forecast, by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class
11.2.4.2. Market Revenue and Forecast, by Disease Indication
11.2.4.3. Market Revenue and Forecast, by Distribution Channel
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class
11.2.5.2. Market Revenue and Forecast, by Disease Indication
11.2.5.3. Market Revenue and Forecast, by Distribution Channel
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class
11.2.6.2. Market Revenue and Forecast, by Disease Indication
11.2.6.3. Market Revenue and Forecast, by Distribution Channel
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class
11.2.7.2. Market Revenue and Forecast, by Disease Indication
11.2.7.3. Market Revenue and Forecast, by Distribution Channel
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class
11.3.2. Market Revenue and Forecast, by Disease Indication
11.3.3. Market Revenue and Forecast, by Distribution Channel
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class
11.3.4.2. Market Revenue and Forecast, by Disease Indication
11.3.4.3. Market Revenue and Forecast, by Distribution Channel
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class
11.3.5.2. Market Revenue and Forecast, by Disease Indication
11.3.5.3. Market Revenue and Forecast, by Distribution Channel
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class
11.3.6.2. Market Revenue and Forecast, by Disease Indication
11.3.6.3. Market Revenue and Forecast, by Distribution Channel
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class
11.3.7.2. Market Revenue and Forecast, by Disease Indication
11.3.7.3. Market Revenue and Forecast, by Distribution Channel
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class
11.4.2. Market Revenue and Forecast, by Disease Indication
11.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class
11.4.4.2. Market Revenue and Forecast, by Disease Indication
11.4.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class
11.4.5.2. Market Revenue and Forecast, by Disease Indication
11.4.5.3. Market Revenue and Forecast, by Distribution Channel
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class
11.4.6.2. Market Revenue and Forecast, by Disease Indication
11.4.6.3. Market Revenue and Forecast, by Distribution Channel
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class
11.4.7.2. Market Revenue and Forecast, by Disease Indication
11.4.7.3. Market Revenue and Forecast, by Distribution Channel
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class
11.5.2. Market Revenue and Forecast, by Disease Indication
11.5.3. Market Revenue and Forecast, by Distribution Channel
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class
11.5.4.2. Market Revenue and Forecast, by Disease Indication
11.5.4.3. Market Revenue and Forecast, by Distribution Channel
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class
11.5.5.2. Market Revenue and Forecast, by Disease Indication
11.5.5.3. Market Revenue and Forecast, by Distribution Channel
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Janssen Global Services, LLC (Johnson & Johnson)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. ALLERGAN.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Amgen Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Other Prominent Players.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck Sharp & Dohme Corp.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample